What is the recommended course of treatment for AF patients requiring OAC undergoing elective PCI/stenting with a low bleeding risk (HAS-BLED 0-2) relative to risk for recurrent ACS and/or stent thrombosis?
In AF patients requiring OAC undergoing elective PCI/stenting, where bleeding risk is low (HAS-BLED 0-2) relative to risk for recurrent ACS and/or stent thrombosis, it is recommended to use triple therapy for 1-3 months, followed by dual therapy with OAC plus single antiplatelet (preferably clopidogrel) until 12 months, following which OAC monotherapy can be used (Weak recommendation, low quality evidence).